Lyell Immunopharma, Inc.
LYEL · Nasdaq · United States
Share price · LYEL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LYEL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+43.3%
- 18 Aug 2026+16.5%
Nothing announced by LYEL that day or the session before.
- 7 Jul 2026+13.3%
Nothing announced by LYEL that day or the session before.
- 30 Jun 2026+10.2%
Nothing announced by LYEL that day or the session before.
- 26 Jun 2026-7.0%
Nothing announced by LYEL that day or the session before.
- 22 Jun 2026-6.0%
Nothing announced by LYEL that day or the session before.
- 3 Jun 2026-15.6%
Nothing announced by LYEL that day or the session before.
- 2 Jun 2026-13.2%
Nothing announced by LYEL that day or the session before.
- 14 Apr 2026-5.8%
Nothing announced by LYEL that day or the session before.
- 13 Apr 2026+10.8%
Nothing announced by LYEL that day or the session before.
Share of unusual movement by asset
For each asset, the share of LYEL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
LYL273events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 20% |
| Sessions with no dated event | — | 80% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CD19 / CD20Cell therapy | Non-Hodgkin Lymphoma Large B-Cell Lymphoma | |
| Phase 1/2 | GCC (guanylyl cyclase C, GUCY2C)Cell therapy | Colorectal Cancer Metastatic Colorectal Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (2)
June 2028 (1)
December 2028 (1)
What to watch
2029 (1)
December 2029 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $41M | $94M+ $85M short-term inv. | $46M-$35M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $40M | $75M+ $131M short-term inv. | $45M-$34M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $37M | $92M+ $163M short-term inv. | $24M-$39M operating cash flow | report ↗ |
| 2025-Q3 | <$0.1M | $28M | $125M+ $196M short-term inv. | $39M-$29M operating cash flow | report ↗ |
| 2025-Q2 | <$0.1M | $35M | $100M+ $178M short-term inv. | $43M-$34M operating cash flow | report ↗ |
| 2025-Q1 | <$0.1M | $43M | $122M+ $181M short-term inv. | $52M-$55M operating cash flow | report ↗ |
| 2024-Q3 | <$0.1M | $40M | $101M+ $340M short-term inv. | $45M-$35M operating cash flow | report ↗ |
| 2024-Q2 | <$0.1M | $40M | $134M+ $358M short-term inv. | $46M-$38M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $43M | $126M+ $401M short-term inv. | $61M-$42M operating cash flow | report ↗ |
| 2023-Q3 | <$0.1M | $44M | $287M+ $289M short-term inv. | $51M-$38M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $47M | $225M+ $371M short-term inv. | $64M-$39M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $45M | $110M+ $503M short-term inv. | $67M-$46M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $42M | $117M+ $532M short-term inv. | $70M-$37M operating cash flow | report ↗ |
| 2022-Q2 | $36M | $44M | $206M+ $450M short-term inv. | $36M-$44M operating cash flow | report ↗ |
| 2022-Q1 | $0.6M | $36M | $223M+ $391M short-term inv. | $68M-$48M operating cash flow | report ↗ |
| 2021-Q3 | $2.8M | $31M | $394M+ $225M short-term inv. | $49M-$26M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | <$0.1M | — | $62M+ $187M short-term inv. | $69M-$150M operating cash flow | report ↗ |
Lyell Immunopharma reported revenue of $0.04M for fiscal year 2025, down 33.3% YoY from $0.06M. R&D spend was not disclosed, cash and equivalents were $61.77M, and the company reported a net loss of $274.45M, with quarterly net burn of $274.45M.
The company is advancing ronde-cel, a dual-targeting CD19/CD20 CAR T-cell candidate, in the pivotal PiNACLE trial for third-line-or-later large B-cell lymphoma and the Phase 3 PiNACLE-H2H trial in the second-line setting, with patient dosing having commenced in February 2026. In November 2025, Lyell acquired an exclusive global license for LYL273, a GCC-targeted CAR T-cell candidate for metastatic colorectal cancer, from Innovative Cellular Therapeutics, and updated clinical data for ronde-cel were presented at the December 2025 ASH annual meeting.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.1M | — | $107M+ $265M short-term inv. | $86M-$162M operating cash flow | report ↗ |
| 2023-FY | $0.1M | $183M | $146M+ $401M short-term inv. | $59M-$164M operating cash flow | report ↗ |
| 2022-FY | $85M | $159M | $124M+ $517M short-term inv. | $46M-$170M operating cash flow | report ↗ |
| 2021-FY | $11M | $139M | $294M+ $321M short-term inv. | $63M-$126M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 4 purchases ($75.0M), 29 sales ($613K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | Bulis Veronica Sanchez · VP, Corporate Controller | Open-market sale | 416 | $15.93 | $7K | Form 4 |
| 2026-11-10 | Seely Lynn · director, President and CEO | Open-market sale | 545 | $15.93 | $9K | Form 4 |
| 2026-11-10 | Hill Stephen J. · Chief Operating Officer | Open-market sale | 88 | $15.93 | $1K | Form 4 |
| 2026-11-10 | Lee Gary K. · Chief Scientific Officer | Open-market sale | 129 | $15.93 | $2K | Form 4 |
| 2026-11-04 | ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT; Burow Kristina; BERNS PAUL L; BYBEE CLINTON · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Open-market purchase | 2,321,262 | $10.77 | $25.0M | Form 4 |
| 2026-11-04 | ARCH Venture Partners IX, LLC; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Partners IX Overage, L.P. · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Open-market purchase | 2,321,262 | $10.77 | $25.0M | Form 4 |
| 2026-10-12 | Aguirre Jarrad Mattieu · Chief Medical Officer | Open-market sale | 422 | $8.63 | $4K | Form 4 |
| 2026-09-10 | Shook David · Chief Medical Officer | Open-market sale | 500 | $12.70 | $6K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 73 reporting institutions held 12.0M shares ($237.0M, 48.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ARCH Venture Management, LLC | 3,247,162 | $65.1M |
| 2 | GSK plc | 1,512,659 | $30.3M |
| 3 | Foresite Capital Management IV, LLC | 800,399 | $16.1M |
| 4 | Orland Properties Ltd | 754,698 | $15.1M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 718,155 | $14.4M |
| 6 | Almitas Capital LLC | 577,807 | $11.6M |
| 7 | Foresite Capital Management V, LLC | 477,078 | $9.6M |
| 8 | MILLENNIUM MANAGEMENT LLC | 458,905 | $9.2M |
| 9 | CITADEL ADVISORS LLC | 381,462 | $7.7M |
| 10 | venBio Partners LLC | 337,697 | $6.8M |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 310,198 | $6.2M |
| 12 | Alphabet Inc. | 293,256 | $5.9M |
| 13 | BlackRock, Inc. | 191,820 | $3.8M |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 166,980 | $3.4M |
| 15 | MARSHALL WACE, LLP | 148,516 | $3.0M |